The new factor Xa inhibitor: Apixaban
Sangeeta Bhanwra1★, Kaza Ahluwalia1★ Corresponding author
- 1Department of Pharmacology, Government Medical College and Hospital, Chandigarh, India Mini Review.
CORRESPONDENCE
Sangeeta Bhanwra
Department of Pharmacology, Government Medical College and Hospital, Chandigarh, India Mini Review.
Volume 5, Issue 1 · pp. 12–14 · PUBLISHED 2014 · DOI: 10.4103/0976-500X.124409
View on J Pharmacol. Pharmacother. original site ↗
ABSTRACT
Cardiovascular diseases are still the most important cause of morbidity and mortality worldwide and anti‑thrombotic treatment is widely used as a result. The currently used drugs include heparin and its derivatives, vitamin K antagonists, though efficacious, have their own set of limitations like unpredictable pharmacokinetic profile, parenteral route (with heparin and its derivatives only), narrow therapeutic window, and constant laboratory monitoring for their efficacy and safety. This lead to the development of novel factor Xa inhibitors which could be given orally, have predictable dose response relationship and are associated with lesser hemorrhagic complications. They include rivaroxaban, apixaban, and edoxaban among others. Apixaban has currently been approved for use in patients undergoing total knee or hip replacement surgery and to prevent stroke in patients with atrial fibrillation. Many trials are ongoing for apixaban to firmly establish its place in future, among the anti‑thrombotic drugs.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Bhanwra, S., & Ahluwalia, K. (2014). The new factor Xa inhibitor: Apixaban. Journal of Pharmacology and Pharmacotherapeutics, 5(1), 12–14. https://doi.org/10.4103/0976-500X.124409